Oppenheimer & CO Inc Gilead Sciences, Inc. Transaction History

Oppenheimer & CO Inc

$6.42 Billion
Q3 2024

A detailed history of Oppenheimer & CO Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 284,508 shares of GILD stock, worth $25.2 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

284,508

Previous 288,472 1.37%

Holding current value

$25.2 Million

Previous $19.8 Million 20.49%

% of portfolio

0.37%

Previous 0.32%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 05, 2024	SELL	$66.59 - $83.99 $263,962 - $332,936	-3,964 Reduced 1.37%	284,508 $23.8 Million
Q2 2024 Aug 07, 2024	SELL	$63.15 - $72.88 $458,405 - $529,035	-7,259 Reduced 2.45%	288,472 $19.8 Million
Q1 2024 May 06, 2024	SELL	$71.58 - $87.29 $236,142 - $287,969	-3,299 Reduced 1.1%	295,731 $21.7 Million
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $2.45 Million - $2.78 Million	-33,399 Reduced 10.05%	299,030 $24.2 Million
Q3 2023 Nov 07, 2023	SELL	$73.94 - $80.67 $600,688 - $655,363	-8,124 Reduced 2.39%	332,429 $24.9 Million
Q2 2023 Aug 02, 2023	SELL	$76.01 - $86.7 $612,640 - $698,802	-8,060 Reduced 2.31%	340,553 $26.2 Million
Q1 2023 May 10, 2023	SELL	$77.31 - $88.08 $209,278 - $238,432	-2,707 Reduced 0.77%	348,613 $28.9 Million
Q4 2022 Feb 07, 2023	SELL	$62.32 - $89.47 $4.15 Million - $5.95 Million	-66,527 Reduced 15.92%	351,320 $30.2 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.46 Million - $1.66 Million	24,461 Added 6.22%	417,847 $25.8 Million
Q2 2022 Aug 08, 2022	SELL	$57.72 - $65.01 $314,862 - $354,629	-5,455 Reduced 1.37%	393,386 $24.3 Million
Q1 2022 May 12, 2022	SELL	$57.92 - $72.58 $1.79 Million - $2.24 Million	-30,819 Reduced 7.17%	398,841 $23.7 Million
Q4 2021 Feb 02, 2022	SELL	$64.88 - $73.64 $1.46 Million - $1.66 Million	-22,549 Reduced 4.99%	429,660 $31.2 Million
Q3 2021 Nov 12, 2021	BUY	$67.69 - $73.03 $2.36 Million - $2.54 Million	34,814 Added 8.34%	452,209 $31.6 Million
Q2 2021 Aug 03, 2021	BUY	$63.47 - $69.35 $4.23 Million - $4.62 Million	66,644 Added 19.0%	417,395 $28.7 Million
Q1 2021 May 10, 2021	BUY	$60.0 - $68.46 $686,400 - $783,182	11,440 Added 3.37%	350,751 $22.7 Million
Q4 2020 Feb 11, 2021	SELL	$56.65 - $64.55 $2.89 Million - $3.29 Million	-51,023 Reduced 13.07%	339,311 $19.8 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $469,910 - $590,831	-7,567 Reduced 1.9%	390,334 $24.7 Million
Q2 2020 Aug 11, 2020	SELL	$72.34 - $84.0 $2.45 Million - $2.84 Million	-33,803 Reduced 7.83%	397,901 $30.6 Million
Q1 2020 May 08, 2020	BUY	$62.63 - $80.22 $3.23 Million - $4.14 Million	51,611 Added 13.58%	431,704 $32.3 Million
Q4 2019 Feb 07, 2020	SELL	$61.62 - $67.78 $339,279 - $373,196	-5,506 Reduced 1.43%	380,093 $24.7 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $590,344 - $651,636	-9,444 Reduced 2.39%	385,599 $24.4 Million
Q2 2019 Aug 09, 2019	SELL	$61.87 - $69.38 $79,441 - $89,083	-1,284 Reduced 0.32%	395,043 $26.7 Million
Q1 2019 Apr 24, 2019	SELL	$62.53 - $70.05 $968,277 - $1.08 Million	-15,485 Reduced 3.76%	396,327 $25.8 Million
Q4 2018 Jan 29, 2019	SELL	$60.54 - $79.0 $202,385 - $264,097	-3,343 Reduced 0.81%	411,812 $25.8 Million
Q3 2018 Oct 26, 2018	BUY	$71.28 - $78.92 $141,419 - $156,577	1,984 Added 0.48%	415,155 $32.1 Million
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $39.1 Million - $45.6 Million	-601,960 Reduced 59.3%	413,171 $29.3 Million
Q1 2018 May 01, 2018	BUY	$72.84 - $88.8 $958,064 - $1.17 Million	13,153 Added 1.31%	1,015,131 $76.5 Million
Q4 2017 Feb 07, 2018	SELL	$71.15 - $83.52 $154,751 - $181,656	-2,175 Reduced 0.22%	1,001,978 $71.8 Million
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $72.4 Million - $85.8 Million	1,004,153	1,004,153 $81.4 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer & CO Inc with notifications on news.

Account

Oppenheimer & CO Inc Gilead Sciences, Inc. Transaction History